Pulmonology Advisor (4/1, Stong) reports, “A notable proportion of Black, Hispanic, and White patients with interstitial lung disease (ILD) may not attain eligibility for antifibrotic therapy, clinical trials, and lung transplant referrals when race-based pulmonary function test (PFT) equations for determining eligibility are used, according to study findings.” Investigators came to this conclusion after evaluating “how the use of different PFT reference equations affected the eligibility of Black, Hispanic/Latino, and White patients with ILD for clinical trials, antifibrotic therapy, and lung transplantation, using data from the Pulmonary Fibrosis Foundation Patient Registry.” The research was published in the Annals of the American Thoracic Society.
